| Name | Cub Pharmacy #4974/792 |
|---|---|
| Organization Name | Supervalu Pharmacies Inc |
| Location | 1020 Diffley Rd, Eagan, Minnesota 55123 |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Phone | (651) 452-5500 |
| Participate in Medicare | Medicare enrolled and may accept medicare assignment. Please check with the supplier if they accept medicare-approved amount before you get your prescription drugs, equipment or supplies from this supplier. |
News Archive
The kinase IKK phosphorylates the protein mutated in Huntington's disease to promote its removal and neuron survival, but IKK may be a double-edged sword that increases neurotoxicity in later stages of the disease. The study, led by researchers from the University of California, Irvine, will be published online December 21 in the Journal of Cell Biology (www.jcb.org).
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the conclusion of the pan-European MitoTarget Project, the EU funded orphan disease project, with submission of the final report to the EC.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the underwriters of its recently completed initial public offering of common stock have exercised their option to purchase an additional 968,539 shares of common stock to cover over-allotments.
A new study has found evidence that marathon running could trigger pulmonary oedema, where fluid builds up in the lungs.
› Verified 7 days ago
| NPI Number | 1598912560 |
| Organization Name | SUPERVALU PHARMACIES INC |
| Doing Business As | CUB PHARMACY |
| Type | Durable Medical Equipment & Medical Supplies Supplier |
| Address | 1020 Diffley Rd, Eagan, MN 55123 |
| Phone Number | 651-452-5500 |
News Archive
The kinase IKK phosphorylates the protein mutated in Huntington's disease to promote its removal and neuron survival, but IKK may be a double-edged sword that increases neurotoxicity in later stages of the disease. The study, led by researchers from the University of California, Irvine, will be published online December 21 in the Journal of Cell Biology (www.jcb.org).
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the conclusion of the pan-European MitoTarget Project, the EU funded orphan disease project, with submission of the final report to the EC.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the underwriters of its recently completed initial public offering of common stock have exercised their option to purchase an additional 968,539 shares of common stock to cover over-allotments.
A new study has found evidence that marathon running could trigger pulmonary oedema, where fluid builds up in the lungs.
› Verified 7 days ago
News Archive
The kinase IKK phosphorylates the protein mutated in Huntington's disease to promote its removal and neuron survival, but IKK may be a double-edged sword that increases neurotoxicity in later stages of the disease. The study, led by researchers from the University of California, Irvine, will be published online December 21 in the Journal of Cell Biology (www.jcb.org).
Trophos SA, a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, announces today the conclusion of the pan-European MitoTarget Project, the EU funded orphan disease project, with submission of the final report to the EC.
AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the underwriters of its recently completed initial public offering of common stock have exercised their option to purchase an additional 968,539 shares of common stock to cover over-allotments.
A new study has found evidence that marathon running could trigger pulmonary oedema, where fluid builds up in the lungs.
› Verified 7 days ago
Cvs Pharmacy #06715 Type: Community/Retail Pharmacy Location: 4241 Jonny Cake Road, Eagan, Minnesota 55122 Phone: (651) 688-7041 | |
Cvs Pharmacy #16138 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 2000 Cliff Lake Rd, Eagan, Minnesota 55122 Phone: (651) 688-8947 | |
Walgreens #5081 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 4220 Lexington Ave S, Eagan, Minnesota 55123 Phone: (651) 686-1090 | |
Wal-mart Pharmacy 10-1786 Type: Durable Medical Equipment & Medical Supplies Supplier Location: 1360 Town Centre Dr, Eagan, Minnesota 55123 Phone: (651) 686-7431 | |
Hy-vee Pharmacy (1165) Type: Community/Retail Pharmacy Location: 1500 Central Park Commons Dr, Eagan, Minnesota 55121 Phone: (651) 405-3662 |